Long-term safety profile of anakinra in patients with severe cryopyrin-associated periodic syndromes

Torbjörn Kullenberg, Malin Löfqvist, Mika Leinonen, Raphaela Goldbach-Mansky, Hans Olivecrona, Torbjörn Kullenberg, Malin Löfqvist, Mika Leinonen, Raphaela Goldbach-Mansky, Hans Olivecrona

Abstract

Objective: Anakinra is approved for the treatment of RA and cryopyrin-associated periodic syndromes (CAPS). While the anakinra safety profile is well established in RA, the long-term safety profile in severe CAPS is less well documented and will therefore be discussed in this report.

Methods: A prospective, open-label, single centre, clinical cohort study was conducted at the National Institutes of Health in the USA, from 2003 to 2010, investigating the efficacy and safety of anakinra treatment for up to 5 years in 43 patients with CAPS. Safety was evaluated using adverse event (AE) reports, laboratory assessments, vital signs and diary reports.

Results: In total, 1233 AEs were reported during the study, with a yearly rate of 7.7 AEs per patient. The event rate decreased over time, and dose escalation during the study did not affect AE frequency. Anakinra had similar safety profiles in adults and children. The most frequently reported AEs were typical CAPS disease symptoms such as headache and arthralgia. Injection site reactions occurred mainly during the first month of anakinra treatment. In total, 14 patients experienced 24 serious AEs (SAEs), all of which resolved during the study period. The most common types of SAEs were infections such as pneumonia and gastroenteritis. There were no permanent discontinuations of treatment due to AEs.

Conclusion: In this study anakinra treatment of patients with severe CAPS for up to 5 years was safe and well tolerated both in paediatric and adult patients, with most AEs emerging during the first months after treatment initiation.

Trial registration: ClincialTrials.gov, clinicaltrials.gov, NCT00069329.

Keywords: adverse event (AE); anakinra; clinical trial; cryopyrin-associated periodic syndromes (CAPS); headache; infections; injection site reactions (ISR); neonatal-onset multisystem inflammatory disease (NOMID); safety.

© The Author 2016. Published by Oxford University Press on behalf of the British Society for Rheumatology.

Figures

F ig . 1
Fig. 1
Exposure per dose level in the study population Exposure per dose level (daily s.c. dose).
F ig . 2
Fig. 2
Adverse event rates by age group and over time (A) Yearly event rate by age at onset for the safety population (n = 43) in infants (<2 years), children (2–11 years), adolescents (12–17 years) and adults (≥18 years). (B) Adverse event rate over time during the study period. In the line representing non-CAPS related AEs the following AEs were excluded: ocular hyperaemia pyrexia, fatigue, malaise, arthralgia, headache, dizziness, rash and urticaria.

References

    1. Hoffman HM. Rilonacept for the treatment of cryopyrin-associated periodic syndromes (CAPS). Expert Opin Biol Ther 2009;9:519–31.
    1. Lachmann HJ, Quartier P, So A, Hawkins PN. The emerging role of interleukin-1beta in autoinflammatory diseases. Arthritis Rheum 2011;63:314–24.
    1. Touitou I, Sarkisian T, Medlej-Hashim M. et al. Country as the primary risk factor for renal amyloidosis in familial Mediterranean fever. Arthritis Rheum 2007;56:1706–12.
    1. Goldbach-Mansky R, Dailey NJ, Canna SW. et al. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. N Engl J Med 2006;355:581–92.
    1. Prieur AM, Griscelli C, Lampert F. et al. A chronic, infantile, neurological, cutaneous and articular (CINCA) syndrome. A specific entity analysed in 30 patients. Scand J Rheumatol Suppl 1987;66:57–68.
    1. Ogura Y, Sutterwala FS, Flavell RA. The inflammasome: first line of the immune response to cell stress. Cell 2006;126:659–62.
    1. Hawkins PN, Lachmann HJ, McDermott MF. Interleukin-1-receptor antagonist in the Muckle-Wells syndrome. N Engl J Med 2003;348:2583–4.
    1. Dinarello CA, Simon A, van der Meer JW. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov 2012;11:633–52.
    1. Sibley CH, Plass N, Snow J. et al. Sustained response and prevention of damage progression in patients with neonatal-onset multisystem inflammatory disease treated with anakinra: a cohort study to determine three- and five-year outcomes. Arthritis Rheum 2012;64:2375–86.
    1. Bresnihan B, Alvaro-Gracia JM, Cobby M. et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 1998;41:2196–204.
    1. Cohen S, Hurd E, Cush J. et al. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002;46:614–24.
    1. Cohen SB, Moreland LW, Cush JJ. et al. A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate. Ann Rheum Dis 2004;63:1062–8.
    1. den Broeder AA, de Jong E, Franssen MJ. et al. Observational study on efficacy, safety, and drug survival of anakinra in rheumatoid arthritis patients in clinical practice. Ann Rheum Dis 2006;65:760–2.
    1. Mertens M, Singh JA. Anakinra for rheumatoid arthritis. Cochrane Database Syst Rev 2009;CD005121..
    1. Kaiser C, Knight A, Nordstrom D. et al. Injection-site reactions upon Kineret (anakinra) administration: experiences and explanations. Rheumatol Int 2012;32:295–9.
    1. Mertens M, Singh JA. Anakinra for rheumatoid arthritis: a systematic review. J Rheumatol 2009;36:1118–25.
    1. Aubert P, Suarez-Farinas M, Mitsui H. et al. Homeostatic tissue responses in skin biopsies from NOMID patients with constitutive overproduction of IL-1beta. PloS One 2012;7:e49408.
    1. Graham NM. The epidemiology of acute respiratory infections in children and adults: a global perspective. Epidemiol Rev 1990;12:149–78.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren